Article, News
Dan Shelly, PhD, on Developing an Allogeneic, Adaptable CAR Platform
We can profile the patient, find out what they need, we pull the appropriate targeting ligand from the freezer, couple it to the cell we…
Media, News
Prescient Therapeutics showcases cell therapy data at prestigious ISCT conference
Prescient Therapeutics Ltd (ASX:PTX) CEO Steven Yatomi-Clarke updates Proactive’s Elisha Newell after the biotech showcased pre-clinical CellPryme and OmniCAR data at the International Society of…
Media, News
New tumour destruction data for Prescient’s OmniCAR and CellPryme platforms
Clinical stage oncology company Prescient Therapeutics (ASX: PTX) presented exciting new data on their OmniCAR and CellPryme cell therapy platforms at the prestigious International Society…
Media, News
Cell Therapies presentations from ISCT
Prescient was pleased to present data on our cell therapies at the prestigious International Society of Cell & Gene Therapy (ISCT) conference in Paris in…
Article, News
Prescient bolsters board, abstracts showcased at prestigious conference
Clinical stage oncology company Prescient Therapeutics (ASX: PTX) has appointed highly experienced US biotech executive Dr Ellen Feigal as a Non-Executive Director of PTX. Dr…
Article, News
Prescient Therapeutics to present OmniCAR and CellPryme abstracts at international gene therapy conference
Clinical stage oncology company Prescient Therapeutics (ASX: PTX) will present two of its abstracts at an annual conference of the International Society of Cell & Gene Therapy…
Article, News
Prescient Therapeutics to present CellPryme and OmniCAR data to International Society of Cell and Gene Therapy
The prestigious International Society of Cell and Gene Therapy (ISCT) will showcase two abstracts from Prescient Therapeutics Ltd (ASX:PTX) at its annual meeting in Paris, which runs…
Article, News
Prescient Therapeutics (ASX:PTX) announces US-based Dr Ellen Feigal as new inclusion to Board
ASX-listed clinical-stage oncology company Prescient Therapeutics (ASX: PTX) has informed about the appointment of Dr Ellen Feigal to PTX’s Board. Notably, Dr Feigal is an…
Article, News
Prescient Therapeutics bolsters board with appointment of experienced US-based pharma executive
Prescient Therapeutics Ltd (ASX:PTX) has strengthened its board through the appointment of experienced pharma executive Dr Ellen Feigal as a US-based independent, non-executive director, effective today….
Article, News
Prescient Therapeutics (ASX:PTX) makes progress in March 2023 quarter
Prescient Therapeutics (ASX: PTX), the Australian listed entity into clinical stage oncology, has released its Activities Report for the quarter ended March 2023. Aside from…